Hygeia Pharmaceuticals Inc. announced Friday that it hassubmitted an investigational new drug (IND) application to FDAon its human monoclonal antibody product for treatingcolorectal cancer.

The drug, Monopharm-C, is a human monoclonal -- producedby in vitro immunization -- that is directed specifically againsta unique antigen found on adenocarcinoma cells, explainedRonald Brown, Hygeia's president and chief operating officer.San Diego-based Hygeia, whose stock trades on the Vancouverstock exchange as HYG, has filed patent applications on both theantigen and the attendant antibodies, Brown told BioWorld.

(c) 1997 American Health Consultants. All rights reserved.

No Comments